Tubulis
AcquiredTubulis is a biotech company in Munich, Germany, founded in 2019. It has raised $578.4M across 3 rounds, most recently a $359.2M Series C in October 2025.
Next-generation antibody-drug conjugates for durable cancer treatment
- Headquarters
- Munich, Bavaria
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- tubulis.com
- Total Funding
- $578.4M
- Last Round
- $359.2M Series COct 2025
- Rounds
- 3
- Acquisition Date
- May 2026
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 3 funding rounds and 15 investors for this company. The full record is or through the API.
About
Tubulis is a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) for the treatment of solid and hematologic tumors. Founded in 2019 in Munich, Germany by Dr. Dominik Schumacher and Dr. Jonas Helma-Smets — both formerly group leaders at Ludwig Maximillian University — the company developed a proprietary ADC platform designed to generate uniquely matched conjugates with superior biophysical properties, delivering durable on-tumor activity and long-lasting anti-tumor effects in preclinical models. Tubulis' lead pipeline programs include TUB-040 (targeting NaPi2b) and TUB-030 (directed against 5T4), both in clinical evaluation for high-need solid tumor indications. The company raised over €308M in its Series C financing round in October 2025 to advance TUB-040 into Phase I/IIa trials. In April 2026, Gilead Sciences announced an agreement to acquire Tubulis in a deal worth up to $5 billion.
Summary
It lists 51–200 employees. It has raised $578.4M in total across 3 rounds, most recently a $359.2M Series C round in Oct 2025. Investors include Andera Partners, Gilead Sciences and Venrock.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
May 2026
Sign up to see all 4 events
Funding: Series B through Series C. Amounts, valuations, and investors where available.
Investors
Andera Partners
2 rounds
Gilead Sciences
1 round

Venrock
1 round
EQT Life Sciences
1 round
Nextech Invest
1 round

BioMedPartners
2 rounds

Fund+
2 rounds
Bayern Kapital
2 rounds
Wellington Management
1 round

Ascenta Capital
1 round
Evotec
1 round
Coparion
1 round
High-Tech Grunderfonds
1 round
OCCIDENT
1 round
Seventure Partners
1 round
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...

Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/tubulis"><img src="https://indexed.vc/api/badge/company/tubulis" alt="Tubulis on Indexed.vc" width="260" height="76" /></a>